Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan versus pantoprazole for NERD and erosive esophagitis
IRCT20251101067844N1Phase 3Recruiting
- Sponsor
- Dr. Abidi Pharmaceuticals
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vonoprazan and pantoprazole in gastroesophageal reflux disease (GERD), Non-erosive Gastroesophageal Reflux Disease (NERD) and erosive esophagitis (EE) (4 arms), sponsored by Dr. Abidi Pharmaceuticals. Primary endpoints: Heartburn-free time, Number of heartburn-free days and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
vonoprazanpantoprazole
03
Conditions
gastroesophageal reflux disease (GERD)Non-erosive Gastroesophageal Reflux Disease (NERD)erosive esophagitis (EE)
Beyond the preview
Go deeper on IRCT20251101067844N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251101067844N1.